FTC takes fresh swipe at drug middlemen, says some prices marked up over 1,000% - MarketWatch
1. FTC criticizes pharmacy-benefit managers for high prescription drug markups. 2. Significant markups generated $7.3 billion for top three PBMs from 2017 to 2022. 3. Regulatory scrutiny may influence pricing strategies of companies like CVS. 4. Middlemen face increased pressure, potentially impacting CVS's drug procurement costs.